nanollose Limited (ASX: NC6) - Share Price
Current share price for NC6 : $0.052 0.001 (1.89%)+
Nanollose Limited (NC6), an ASX-listed company, is a biomaterials company commercialising scalable technology to create fibres, fabrics and other novel materials with minimal environmental impact. Its, eco-friendly fermentation process can use agricultural waste and by-products to produce cellulose, a raw material traditionally produced from trees via the wood pulping process. The company then uses this ‘Tree-Free' cellulose as an input for its range of biomaterials including its Nullarbor fibres, MicroGel horticultural medium, and its emerging animal-free and plastic-free leather-like materials.
NC6 General Information +
| ASX Code | NC6 |
| Website | http://www.nanollose.com |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 21 |
| NC6 Share Price | $0.052 |
| Day High | $0.053 |
| Day Low | $0.052 |
| Last Close | $0.053 |
| NC6 Share Price Movement | $0.00 ( 1.89% ) |
Prices as at 16:40, 15 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
nanollose Limited (NC6) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from nanollose Limited (NC6) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
nanollose Limited (NC6) price-sensitive announcements
NC6 - Quarterly Activities/Appendix 4C Cash Flow Report
Nanollose Limited reported significant progress in its quarterly activities for the period
nanollose Limited (NC6)
30 Apr 2026 | 5:22 PM
30 Apr 2026 | 5:22 PM
NC6 - Half Yearly Report and Accounts
Nanollose Limited's half-yearly report for the period ended 31 December 2025 reveals a sig
nanollose Limited (NC6)
27 Feb 2026 | 9:23 AM
27 Feb 2026 | 9:23 AM
NC6 - Quarterly Activities/Appendix 4C Cash Flow Report
Nanollose Limited reported their operational and financial activities for the quarter endi
nanollose Limited (NC6)
30 Jan 2026 | 8:43 AM
30 Jan 2026 | 8:43 AM
NC6 - Quarterly Activities/Appendix 4C Cash Flow Report
Nanollose Limited (ASX: NC6) released its Quarterly Activities and Appendix 4C Cash Flow R
nanollose Limited (NC6)
31 Oct 2025 | 8:11 AM
31 Oct 2025 | 8:11 AM
nanollose Limited (NC6) Recent ASX Announcements
NC6 Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2025A | -$1.43 | -$0.70 | -2.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.17 | -$0.70 | -7.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2023A | -$1.19 | -$0.80 | -24.50% | 0.00 | 0.00 | 0.00% | 0.0% |
NC6 Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | 2023 A | 2024 A | 2025 A | ||
| CSL Limited (CSL) | $51,488M | 0.1108 | -0.1355 | 0.0438 | 11.5284 | 13.3357 | 12.7765 | 4.15% | 3.33% | 3.46% |
| Clinuvel Pharmaceuticals Limited (CUV) | $452M | 0.0287 | 0.0233 | 0.0942 | 12.4791 | 12.1955 | 11.1457 | 0.56% | 0.81% | 1.31% |
| Mesoblast Limited (MSB) | $2,524M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| nanollose Limited (NC6) | $22M | -0.0282 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,616M | -1.3893 | 0.0000 | -0.1297 | 0.0000 | 255.6391 | 293.7365 | 0.00% | 0.00% | 0.00% |
NC6 Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 40.00 | 0.00 |
| Market | 0.29 | 13.20 | 1.18 | 0.70 |
| Sector | 0.39 | 27.30 | 2.56 | 2.17 |
NC6 Directors
| Name | Position | Start Date |
|---|---|---|
| Dr Wayne Morris Best | Executive Chairman, Executive Director | 26 Sep 2014 |
| Mr Winton William Willesee | Non-Executive Director | 8 Sep 2014 |
| Mr Andrew Moullin | Non-Executive Director | 14 Jul 2025 |
nanollose Limited (NC6) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Aug 2025 | MOULLIN, Andrew | Buy | Indirect Shares | 100,000 | $0.083 | $8,300.000 |
| 27 Feb 2025 | WILLESEE, Winton | Issued | Indirect Shares | 3,089,500 | $0.016 | $49,432.000 |
| 27 Feb 2025 | WILLESEE, Winton | Issued | Indirect Shares | 12,500,000 | $0.016 | $200,000.000 |
See all changes in directors' interest & trades for nanollose Limited (NC6) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
NC6 Management
| Name | Position |
|---|---|
| Erlyn Dawson | Company Secretary |
NC6 Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in nanollose Limited (NC6). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 25,019,970 (8.21%) | WACC Pty Ltd |
| 24,858,006 (8.15%) | Azalea Family Holdings Pty Ltd |
| 22,400,000 (7.35%) | Wayne Best |
| 20,625,000 (6.77%) | ConBrio Beteiligungen AG |
NC6 Calendar of Events
| Date | Event |
|---|---|
| 26 February 2027 | Report (Interim) |
| 28 August 2026 | Report (Annual) |
| 28 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
